Detailed Information

Cited 5 time in webofscience Cited 5 time in scopus
Metadata Downloads

Report of aids-related lymphoma in South Koreaopen access

Authors
Kim, Jin-SooKim, Seok JinKim, Jin-SeokKim, Eun SunShin, Ho-JinChung, Joo SeopMin, Yoo-HongLee, Moon HeeChoi, Young JinBang, Soo-MeeKim, Jung A.Cho, Goon JaeChi, Hyun-SookJang, Seong SooPark, Chan JeoungSuh, CheolwonPark, Chong WonKim, Chul Soo
Issue Date
Feb-2008
Publisher
OXFORD UNIV PRESS
Keywords
lymphoma; AIDS-related; anti-retroviral therapy; highly active; chemotherapy; combination; radiotherapy
Citation
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, v.38, no.2, pp 134 - 139
Pages
6
Indexed
SCIE
SCOPUS
Journal Title
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume
38
Number
2
Start Page
134
End Page
139
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35752
DOI
10.1093/jjco/hym168
ISSN
0368-2811
1465-3621
Abstract
Background: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea. The aim of this study is to identify the clinical features of ARL in South Korea. Methods: From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL from seven institutions. Results: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24-72). The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included. Ten of 23 (43.5%) was receiving highly active anti-retroviral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were given combination chemotherapy with/without radiation, four were given radiation alone, and four did not receive any treatment against medical advice. Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes. The response to treatment included CR in eight (44.4%), PR in four (22.2%) and PD in three (16.7%). The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded. Estimated median survival time was 43.9 months. Conclusions: Although the population of patients is small, this is the first clinical data analyses of Korean ARL patients. As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE